Newcelx Ltd. annual report, Q4 FY2020

Business context and reporting period

This is NLS Pharmaceutics Ltd.’s Form 20-F for the fiscal year ended December 31, 2020, prepared under U.S. GAAP. The request identifies “Newcelx Ltd.,” but the filing’s registrant is NLS Pharmaceutics Ltd.; verify the intended company. This is an annual report, not a standalone fourth-quarter filing.

NLS is a clinical-stage biopharmaceutical company developing mazindol controlled-release candidates: Quilience for narcolepsy and Nolazol for ADHD. Neither candidate was approved for sale, and the company reported no product-sales revenue.

Financial results and liquidity

Operating expenses fell 45% and net loss fell 47% year over year, mainly because the company deferred nonessential R&D and business spending pending its IPO. R&D expense declined 89%; management said certain R&D activities were paused. Other expense rose to $328,365, primarily due to foreign-exchange differences. The company recognized no income-tax expense.

At year-end, cash and cash equivalents were $93,711; current assets were $196,711 versus current liabilities of $7.20 million, a working-capital deficit of approximately $7.0 million. Total liabilities were $10.20 million, total assets $1.21 million, shareholders’ deficit $8.98 million, and accumulated deficit $29.76 million. The $2.5 million Eurofarma upfront payment remained deferred revenue, not recognized revenue. No operating margin is meaningful because there was no revenue.

After year-end, the February 2021 IPO raised $17 million net. The company said cash, including IPO proceeds, was expected to fund operations into the second quarter of 2022. It also reported repaying outstanding loans and notes, including accrued interest, in February 2021. These are subsequent events, not year-end 2020 cash or debt balances.

Material changes versus prior periods

• Loss narrowed from 2019, but cash used in operations increased from $190,009 to $729,386.
• Comparative 2019 and 2018 R&D and G&A classifications were restated: intellectual-property costs were reclassified from R&D to G&A. The filing says the correction did not change total operating expenses, net loss, loss per share, or the balance sheet.
• The company disclosed that its previously issued 2019 and 2018 statements should no longer be relied upon because of misstatements described in the notes; the stated correction was a classification error.
• In March 2021, NLS licensed Novartis’s historical mazindol data, subject to upfront and potential milestone and other payments. The filing also describes the 2021 IPO and subsequent debt repayment.

Outlook, risks and unusual items

Management planned to submit a Quilience IND in Q2 2021 and begin a Phase 2 narcolepsy trial in Q3 2021, targeting topline results by year-end 2021. A Phase 3 program was contemplated for the second half of 2022, subject to successful results, regulatory authorization, and additional capital. For Nolazol, management cited a completed Phase 2 adult ADHD trial and planned further Phase 3 development; these are plans, not assured outcomes.

• The auditor’s report includes an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern. NLS had recurring losses, minimal year-end cash, and expected to need substantial additional financing. The IPO improved near-term liquidity but did not eliminate development-funding risk.
• Disclosure controls were found ineffective at December 31, 2020 due to material weaknesses, including inadequate segregation of duties and insufficient personnel with U.S. GAAP and SEC-reporting expertise. Remediation was ongoing; auditor attestation of internal controls was not included.
• COVID-19 could delay trials, patient enrollment, operations, or supply, although the financial-statement note says the company had not then experienced adverse effects on clinical development or financing and the future impact remained uncertain.
• NLS depended on third parties for manufacturing and clinical work and disclosed a single mazindol supplier, no firm future supply commitments, and no internal manufacturing capacity.
• The portfolio depends substantially on mazindol and regulatory success. Quilience had not yet entered sponsored clinical trials; neither candidate had marketing approval. The company also cited regulatory-pathway uncertainty, competition, patent limitations, controlled-substance requirements, and potential future financing dilution.
• Management reported no material legal proceedings during the period. The company had not paid dividends and did not expect to do so in the foreseeable future.

Important facts for investors to verify

• Confirm the issuer identity: the supplied filing is for NLS Pharmaceutics Ltd., not Newcelx Ltd.
• Review the audited statements and restatement note, including the basis for the non-reliance conclusion on prior 2019 and 2018 statements.
• Verify post-IPO cash, debt repayment, actual cash burn, and whether the stated Q2 2022 runway remained achievable.
• Track regulatory clearances, clinical-trial start dates and results for both candidates, and any changes to management’s development timetable.
• Assess whether internal-control remediation is effective and whether the company has strengthened accounting and financial-reporting resources.
• Check the status and terms of mazindol supply arrangements, regulatory acceptance of the proposed development pathway, and any additional financing or dilution.